Journal article

Determining the Optimal Dose of Adenosine for Unmasking Dormant Pulmonary Vein Conduction Following Atrial Fibrillation Ablation: Electrophysiological and Hemodynamic Assessment. DORMANT-AF Study

Sandeep Prabhu, Vincent Mackin, Alex JA Mclellan, Phan Tuong, Desmond Mcglade, Liang-Han Ling, Kah Y Peck, Alexandr Voskoboinik, Bupesh Pathik, Chrishan J Nalliah, Geoff R Wong, Sonia M Azzopardi, Geoffrey Lee, Justin Mariani, Andrew J Taylor, Jonathan M Kalman, Peter M Kistler



INTRODUCTION: ELECTROPHYSIOLOGICAL AND HEMODYNAMIC ASSESSMENT. DORMANT-AF STUDY: The significance of adenosine induced dormant pulmonary vein (PV) conduction in atrial fibrillation (AF) ablation remains controversial. The optimal dose of adenosine to determine dormant PV conduction is yet to be systematically explored. METHODS AND RESULTS: ELECTROPHYSIOLOGICAL AND HEMODYNAMIC ASSESSMENT. DORMANT-AF STUDY: Consecutive patients undergoing index AF ablation received 3 adenosine doses (12, 18, and 24 mg) in a randomized blinded order, immediately after pulmonary vein isolation (PVI). Electrophysiological (PR prolongation, AV block (AVB) and PV reconnection) and hemodynamic (BP) parameters were m..

View full abstract


Funding Acknowledgements

Drs. Sandeep Prabhu, Ling- Han Ling, Alexandr Voskoboinik, Geoff Lee, Chrishan J. Nalliah, and Bupesh Pathik receive funding from Australian National Health and Medical Research Council (NHMRC) and/or National Heart Foundation of Australia. Dr. Geoff R. Wong receives funding from the Cardiac Society of Australia and New Zealand. Drs. Sandeep Prabhu and Alexandr Voskoboinik also receive funding from the Baker IDI Heart and Diabetes Research Institute. Professor Jonathan M. Kalman is in part supported by the NHMRC. Professor M. Kistler is supported by practitioner fellowships from the NHMRC. This research is supported in part by the Victorian Government's Operational Infrastructure Funding.Dr. Kalman reports participation on research grants from Medtronic, Biosense Webster, St. Jude Medical, and Boston Scientific; speaker's bureau compensation from Medtronic and Boston Scientific; and serving on advisory boards of Biosense Webster and Boston Scientific. Other authors: No disclosures.